3
Announcements
Trials
Browse
Landscape
Sponsor
Conditions
Small Cell Lung Carcinoma
9
Carcinoma, Non-Small-Cell Lung
7
Sarcoma
5
Breast Neoplasms
4
Triple Negative Breast Neoplasms
3
Nasopharyngeal Carcinoma
3
Thyroid Neoplasms
2
Pancreatic Neoplasms
2
Neoplasm Metastasis
2
Esophageal Squamous Cell Carcinoma
2
Carcinoma, Renal Cell
2
Carcinoma, Hepatocellular
2
Whole-Brain Radiotherapy
1
Stomach Neoplasms
1
Solid Tumors
1
Small Cell Lung Cancer Extensive Stage
1
Sarcoma, Synovial
1
Sarcoma, Alveolar Soft Part
1
Recurrence
1
Proteinuria
1
Progression Free Survival(PFS)
1
Platinum-resistant Ovarian Cancer (PROC)
1
Ovarian Neoplasms
1
Lung Neoplasms
1
Leiomyosarcoma
1
HER2-Negative Breast Cancer
1
Gallbladder Neoplasms
1
Fallopian Tube Neoplasms
1
Extensive Stage Lung Small Cell Cancer
1
Esophageal Neoplasms
1
Interventions
fludarabine
4
Cyclophosphamide
4
Cisplatin
4
pembrolizumab
3
atezolizumab
3
Pemetrexed
3
fludarabine phosphate
2
entrectinib
2
durvalumab
2
cobimetinib
2
capmatinib
2
alectinib
2
Whole-Body Irradiation
2
Vemurafenib
2
Tacrolimus
2
Peripheral Blood Stem Cell Transplantation
2
Patient Reported Outcome Measures
2
Paclitaxel
2
Nivolumab
2
Mycophenolic Acid
2
Mesna
2
Melphalan
2
Busulfan
2
130-nm albumin-bound paclitaxel
2
trametinib
1
spartalizumab
1
ruxolitinib
1
repotrectinib
1
pralsetinib
1
ponatinib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
0 trials
Recent
Start date
Enrollment
Neoplasms by Histologic Type
×
anlotinib
×
1 year
×
Clear all
No trials found.